Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients
Status:
Withdrawn
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to evaluate efficacy and safety of treatment with 600 mg of BID BI
207127 in combination with 120 mg QD Faldaprevir and RBV compared to a Telaprevir-based
regimen along with PegIFN and RBV in chronically infected HCV GT1 treatment naïve patients,
including patients with compensated cirrhosis.